Selective Laser Trabeculoplasty for Primary Angle-Closure Glaucoma: a pilot case study

ISRCTN ISRCTN42557387
DOI https://doi.org/10.1186/ISRCTN42557387
Secondary identifying numbers N/A
Submission date
05/05/2006
Registration date
03/07/2006
Last edited
11/08/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Michael Belkin
Scientific

Goldschleger Eye Research Institute
Tel Aviv University
Sheba Medical Center
Tel Hashomer
52621
Israel

Study information

Study designProspective, observational, uncontrolled, non-comparative study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymSLT for PACG Study
Study objectivesTo determine whether selective laser trabeculoplasty (SLT) using a Q-switched frequency doubled neodymium-doped yttrium aluminium garnet (Nd:YAG) laser is effective in lowering intraocular pressure in patients with primary angle-closure glaucoma (PACG).
Ethics approval(s)Ethics approval received from:
1. Singapore Eye Research Institute (SERI-Singapore) (Ref: R424/19/2005) dated 27/10/2005
2. United Christian Hospital (Hong Kong) (Ref: KC/KE05-0073/FR-3) dated on 15/06/2005

Other ethics approval from Chulalongkorn University and Hospital (Thailand), St. Luke's Medical Centre (Philippines) and National University Hospital (Singapore).
Health condition(s) or problem(s) studiedPrimary angle-closure glaucoma
InterventionSelective laser trabeculoplasty (SLT)
Intervention typeOther
Primary outcome measureIntraocular pressure (IOP) at regular intervals of follow-up with the final IOP being measured at six months after the last treatment. Successful outcome defined as greater or equal to 20% reduction in IOP from pre-laser levels.
Secondary outcome measuresIOP measured on other eye if both eyes are eligible for the study.
Overall study start date01/07/2005
Completion date01/07/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants150
Key inclusion criteria1. PACG
2. Intraocular pressure 21 - 28 mmHg on one or more topical medicine in presence of patent iridotomy
3. At least two months since last iridotomy
4. Aged over 21 years old
Key exclusion criteria1. Secondary causes of angle-closure
2. Corneal abnormalities
3. Advanced glaucomatous optic neuropathy
4. Patient blind in one eye
Date of first enrolment01/07/2005
Date of final enrolment01/07/2006

Locations

Countries of recruitment

  • Hong Kong
  • Israel
  • Philippines
  • Singapore
  • Thailand

Study participating centre

Goldschleger Eye Research Institute
Tel Hashomer
52621
Israel

Sponsor information

Ellex Medical Pty. Ltd. (Australia)
Industry

82 Gilbert Street
Adelaide, SA
5000
Australia

Website http://www.ellex.com

Funders

Funder type

Industry

Ellex Medical Pty Ltd (Australia)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan